Inhibition of PCSK9 doesn’t just lower cholesterol. It may also slow aging of the cardiovascular system, and other organ systems like the liver. This is an exciting new research area that connects cardiology with the science of aging.
Note that it’s not just drugs that inhibit PCSK9. Many botanical compounds do as well (e.g. berberine). See comments for a list.
——
Quoted:
“In conclusion, PCSK9’s association with cardiovascular aging is a rapidly evolving area of research with significant implications for our understanding of age-related cardiovascular disease. Studies measuring plasma PCSK9 levels, along with investigations into the links between liver health, lipid metabolism, and cardiac function, have begun to uncover the intricate relationships between PCSK9 and cardiovascular aging. The cumulative evidence from various studies suggests that PCSK9 inhibition offers a promising avenue for ameliorating age-related cardiac and hepatic pathologies by targeting both systemic and local factors. Importantly, a recent multivariate genome-wide analysis of aging-related traits identified PCSK9 as a potential new drug target for healthy aging [26]. As the understanding of PCSK9’s multifaceted role in aging and age-related diseases continues to evolve, exploring the therapeutic potential of PCSK9 inhibition in the context of cardiometabolic aging remains an exciting and dynamic area of research.”




